Among them, dasatinib can inhibit the proliferation of squamous cell carcinoma (SQCC) with DDR2 mutation, and ponatinib is prescribed to treat imatinib-resistant patients with CML (88, 92). This evidence concerns the gene DDR2 and chronic myelogenous leukemia, BCR-ABL1 positive.